Next Article in Journal
Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges
Previous Article in Journal
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head
Article Menu

Export Article

Open AccessReview
Vaccines 2015, 3(2), 263-292; doi:10.3390/vaccines3020263

National Differences in Requirements for Ethical and Competent Authority Approval for a Multinational Vaccine Trial under the EU Directive 2001/20/EC

1
Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands
2
Unit of Pharmacotherapy and Pharmaceutical Care, Department of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands
3
Department of Clinical Pharmacy and Pharmacology, University Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Received: 8 October 2014 / Revised: 24 March 2015 / Accepted: 27 March 2015 / Published: 14 April 2015
View Full-Text   |   Download PDF [414 KB, uploaded 14 April 2015]

Abstract

Obtaining approval for a multinational vaccine trial from an ethics committee and the national competent authority of different Member States of the European Union (EU) is challenging under clinical trial Directive 2001/20/EC because of the differences in the implementation of the directive in national laws of Member States. In this review the national differences in requirements for ethical and competent authority approval are illustrated. The national ethical and competent authority review procedures in Finland, Hungary, The Netherlands, Norway and Slovenia are described under the EU trial directive after discussing the provisions of the trial directive related to both review procedures. The review illustrates the differences between the countries in the documents that have to be submitted for the review procedures, the submission procedures and the language requirements of the documents, the organization of the ethics committees and the role of the competent authority in the approval procedure. View Full-Text
Keywords: clinical trial; vaccine; directive 2001/20/EC; approval documentation clinical trial; vaccine; directive 2001/20/EC; approval documentation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

van Doorn, E.; Hak, E.; Wilffert, B. National Differences in Requirements for Ethical and Competent Authority Approval for a Multinational Vaccine Trial under the EU Directive 2001/20/EC. Vaccines 2015, 3, 263-292.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top